ArticleThoracic cancer2020
Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1
Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 27 citations in OpenAlex.
- Unraveling the tapestry: Lessons from multi-omics and spatial biology in hepatocellular cancer.Hepatology (Baltimore, Md.) · 2026Review
- The clinicopathologic characteristics and tumor immune microenvironment of pulmonary enteric adenocarcinoma.Annals of medicine · 2025Article
- Reprogramming the tumor microenvironment: synergistic mechanisms of antibody-drug conjugates and immune checkpoint inhibitors.Antibody therapeutics · 2025Review
- Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy.Journal of experimental & clinical cancer research : CR · 2025Review
- Expression of T cell-related proteins in breast ductal carcinomaHistology and histopathology · 2025Article
- Double-Multiplex Immunostainings for Immune Profiling of Invasive Breast Carcinoma: Emerging Novel Immune-Based Biomarkers.International journal of molecular sciences · 2025Review
- Spatial proximity of CD8NPJ breast cancer · 2025Article
- Immune Checkpoint Inhibitors Combined with Oncolytic Virotherapy: Synergy, Heterogeneity, and Safety in Cancer Treatment.Oncology research · 2025Review
- HER2-positive breast cancer with invasive micropapillary carcinoma component shows immunosuppressive microenvironment and resistance to neoadjuvant therapy.Frontiers in immunology · 2025Article
- Virtual multiplex immunofluorescence identifies lymphocyte subsets predictive of response to neoadjuvant therapy.Therapeutic advances in medical oncology · 2025Article
- To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment.Frontiers in immunology · 2024Article
- Review
- Predictive model based on multiple immunofluorescence quantitative analysis for pathological complete response to neoadjuvant immunochemotherapy in lung squamous cell carcinoma.Frontiers in oncology · 2024Article
- Components of the tumor immune microenvironment based on m-IHC correlate with prognosis and subtype of triple-negative breast cancer.Cancer medicine · 2023Article
- Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast CancerThe Journal of pathology · 2023Review
- GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC.Cancers · 2023Article
- Article
- Neoadjuvant chemotherapy for breast cancer: an evaluation of its efficacy and research progress.Frontiers in oncology · 2023Review
- Clinical implications of T cell exhaustion for cancer immunotherapy.Nature reviews. Clinical oncology · 2022Review
- SPCS: a spatial and pattern combined smoothing method for spatial transcriptomic expression.Briefings in bioinformatics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to explore the potentially predictive role and dynamic changes of immune checkpoints on T cell subsets in patients with breast cancer receiving neoadjuvant chemotherapies.
methodsFluorescent multiplex immunohistochemistry (mIHC) was used to stain CD4, CD8, PD1, TIM3, and cytokeratins simultaneously in paired breast cancer samples before and after neoadjuvant therapies (NAT) in a prospective cohort (n = 50). Singleplex IHC was conducted to stain for CD3 in 100 cases with inclusion of extra retrospective 50 cases. Cell levels were correlated with clinicopathological parameters and pathological complete response (pCR).
resultsIn pretreatment tumors, the percentages of infiltrating CD8
conclusionsPD1 KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: PD1 WHAT THIS STUDY ADDS: Incremental levels of PD1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.